Abstract

ABSTRACT Purpose Sarcoidosis is a systemic granulomatous inflammatory disease with varying clinical presentations, including sarcoid uveitis, which is the most prevalent ocular manifestation of sarcoidosis and differs by region and ethnicity. This study aims to determine the incidence and prevalence of sarcoidosis-related uveitis in South Korea, providing essential epidemiological data. Methods This nationwide, population-based retrospective study used the Korean Health Insurance Review and Assessment database from 2010 to 2019. It included all individuals diagnosed with sarcoidosis (ICD-10 code D86) and focused on those with newly developed uveitis. We assessed annual incidence, prevalence, gender-specific trends, age at diagnosis, treatment patterns, and recurrence. Cases were categorized as single episode or recurrent/chronic based on treatment duration and interval before recurrence. Results Among 9,485 patients with sarcoidosis, 2,730 (28.8%) had sarcoidosis-related uveitis, with 2,413 (88.4%) being recurrent/chronic. Anterior uveitis was the most common presentation (78.0%), with posterior segment involvement in 22.0% of cases. The peak age of onset was 50–59 years for both genders. The incidence rate was 0.33 and 0.64 per 100,000 for men and women, respectively. The prevalence was 0.18 and 0.35 per 100,000 for men and women, respectively. Among sarcoidosis patients, 32.9% with uveitis used three or more combinations of systemic steroids and immunosuppressants, compared to 11.1% without uveitis. Conclusion The high prevalence of sarcoid uveitis in sarcoidosis patients necessitates regular ophthalmic examinations. Our findings highlight the need for comprehensive eye care in managing sarcoidosis and suggest that uveitis may increase disease severity, warranting tailored treatment and enhanced monitoring protocols in Korea.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.